1239963-73-5

Basic information

• Product Name: 1-amino-3-(3,4-dimethoxyphenyl)-3-methylbutan-2-one hydrochloride
• Synonyms: 1-amino-3-(3,4-dimethoxyphenyl)-3-methylbutan-2-one hydrochloride
• CAS NO: 1239963-73-5
• Molecular Weight: 273.76
• Mol File: 1239963-73-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-amino-3-(3,4-dimethoxyphenyl)-3-methylbutan-2-one hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 1-amino-3-(3,4-dimethoxyphenyl)-3-methylbutan-2-one hydrochloride(1239963-73-5)
• EPA Substance Registry System: 1-amino-3-(3,4-dimethoxyphenyl)-3-methylbutan-2-one hydrochloride(1239963-73-5)

Safety Data

• Hazardous Substances Data: 1239963-73-5(Hazardous Substances Data)

Upstream product

• 717105-57-2 2-(3,4-dimethoxyphenyl)-2-methylpropanal 
• 1239963-71-3 3-(3,4-dimethoxyphenyl)-3-methyl-1-nitrobutan-2-ol 
• 4461-99-8 3-(3,4-dimethoxyphenyl)-3-methylbutan-2-one 
• 1430211-87-2 1-bromo-3-(3,4-dimethoxyphenyl)-3-methylbutan-2-one 
• 23023-16-7 2‐(3,4‐dimethoxyphenyl)‐2‐methylpropionitrile 
• 1239963-72-4 3-(3,4-dimethoxyphenyl)-3-methyl-1-nitrobutan-2-one 

Downstream Products

• 1239963-74-6 5-(2-(3,4-dimethoxyphenyl)propan-2-yl)-1-(4-fluorophenyl)-1H-imidazole-2(3H)-thione 
• 1239956-58-1 2-(2-chloro-4-fluorobenzylthio)-5-(2-(3,4-dimethoxyphenyl)propan-2-yl)-1-(4-fluorophenyl)-1H-imidazole 
• 1239963-74-6 5-(2-(3,4-dimethoxyphenyl)propan-2-yl)-1-(4-fluorophenyl)-1H-imidazole-2-thiol 
• 1430210-54-0 2-((2-(4-(1H-imidazol-1-yl)phenoxy)ethyl)thio)-5-(2-(3,4-dimethoxyphenyl)propan-2-yl)-1-(4-fluorophenyl)-1H-imidazole 

Relevant articles and documents

Practical and Efficient Synthesis of 2-Thio-imidazole Derivative - ZY12201: A Potent TGR5 Agonist

Early scalable process development for the synthesis of ZY12201, a novel TGR5 receptor agonist, as a potential clinical candidate is described. A practical, efficient, and scalable synthetic route provided ZY12201 in seven steps and 32% overall yield. The

TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY

The present invention comprises TGR5 agonists of structural formula I, wherein X, R1, R2, and R5 are defined herein, as well as N-oxides of them and pharmaceutically acceptable salts thereof. The invention further comprise